EyePoint Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 EyePoint Pharmaceuticals Inc 公司

EyePoint Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療眼部疾病的眼科產品。該公司的產品線利用其 Durasert 技術 (Durasert) 進行持續眼內藥物輸送，包括輸送 EYP-1901，這是一種針對抗血管內皮生長因子 (anti-VEGF) 介導的視網膜疾病的試驗性持續輸送治療。其其他產品線計劃包括 EYP-2301，一種有前途的 TIE-2 激動劑，razuprotafib，以 Durasert E 配製，可能改善嚴重視網膜疾病的結果。EYP-1901 目前處於 2 期臨牀試驗階段，作爲溼性老年性黃斑變性 (wet AMD)、非增生性糖尿病視網膜病變 (NPDR) 和糖尿病性黃斑水腫 (DME) 的持續輸送治療。該公司的其他產品包括 YUTIQ 和 DEXYCU。

EyePoint Pharmaceuticals Inc簡介



公司代碼EYPT

公司名稱EyePoint Pharmaceuticals Inc

上市日期Jan 27, 2005

CEODr. Jay S. Duker, M.D.

員工數量165

證券類型Ordinary Share

年結日Jan 27

公司地址480 Pleasant Street, Suite C400

城市WATERTOWN

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編02472

電話16179265000

網址https://eyepointpharma.com/

公司代碼EYPT

上市日期Jan 27, 2005

CEODr. Jay S. Duker, M.D.

EyePoint Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

41.78K

--

Dr. Reginald J Sanders, M.D.

Non-Executive Independent Director

--

Mr. Fred Hassan

Non-Executive Independent Director

--

Mr. Stern

Investor Relations

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

YUTIQ

3.10M

7.16%

地區USD

名稱

營收

佔比

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

業務

地區

業務USD

名稱

營收

佔比

YUTIQ

3.10M

7.16%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

Cormorant Asset Management, LP

10.06%

Suvretta Capital Management, LLC

8.22%

Adage Capital Management, L.P.

8.21%

BlackRock Institutional Trust Company, N.A.

5.56%

Franklin Advisers, Inc.

5.15%

其他

62.80%

持股股東

佔比

Cormorant Asset Management, LP

10.06%

Suvretta Capital Management, LLC

8.22%

Adage Capital Management, L.P.

8.21%

BlackRock Institutional Trust Company, N.A.

5.56%

Franklin Advisers, Inc.

5.15%

其他

62.80%

股東類型

持股股東

佔比

Hedge Fund

33.33%

Investment Advisor

23.07%

Investment Advisor/Hedge Fund

20.71%

Research Firm

3.68%

Individual Investor

2.96%

Venture Capital

2.92%

Private Equity

1.68%

Bank and Trust

0.95%

Pension Fund

0.14%

其他

10.56%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

378

69.28M

83.75%

-19.64M

2025Q2

385

78.45M

113.85%

-10.49M

2025Q1

386

76.27M

110.90%

-11.90M

2024Q4

373

75.75M

111.39%

+202.32K

2024Q3

358

60.55M

112.89%

-8.01M

2024Q2

345

60.80M

116.35%

-2.75M

2024Q1

328

57.32M

114.97%

+528.95K

2023Q4

282

52.72M

108.16%

+11.49M

2023Q3

239

37.39M

106.16%

-1.26M

2023Q2

224

35.30M

102.90%

-4.83M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Cormorant Asset Management, LP

8.32M

12.08%

--

Jun 30, 2025

Suvretta Capital Management, LLC

6.80M

9.87%

--

Jun 30, 2025

Adage Capital Management, L.P.

6.80M

9.87%

+600.00K

+9.68%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.60M

6.67%

-346.31K

-7.00%

Jun 30, 2025

Franklin Advisers, Inc.

4.27M

6.19%

+148.48K

+3.60%

Jun 30, 2025

The Vanguard Group, Inc.

3.80M

5.52%

-15.98K

-0.42%

Jun 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

5.2%

-128.17K

-3.45%

Jun 30, 2025

TCG Crossover Management, LLC

3.57M

5.18%

--

Jun 30, 2025

Citadel Advisors LLC

2.34M

3.4%

+58.12K

+2.54%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.59M

2.31%

-982.00

-0.06%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

1.16%

Simplify Health Care ETF

1.02%

SPDR S&P Pharmaceuticals ETF

0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.73%

Invesco Dorsey Wright SmallCap Momentum ETF

0.39%

Federated Hermes MDT Small Cap Core ETF

0.3%

iShares Micro-Cap ETF

0.16%

Invesco Nasdaq Biotechnology ETF

0.1%

Vanguard US Momentum Factor ETF

0.1%

ProShares Ultra Nasdaq Biotechnology

0.1%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.16%

Simplify Health Care ETF

佔比1.02%

SPDR S&P Pharmaceuticals ETF

佔比0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比0.73%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.39%

Federated Hermes MDT Small Cap Core ETF

佔比0.3%

iShares Micro-Cap ETF

佔比0.16%

Invesco Nasdaq Biotechnology ETF

佔比0.1%

Vanguard US Momentum Factor ETF

佔比0.1%

ProShares Ultra Nasdaq Biotechnology

佔比0.1%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

公告日期

類型

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1